Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xenetic Biosciences Inc

2.79
+0.09743.61%
Post-market: 2.860.0676+2.42%16:00 EDT
Volume:7.45K
Turnover:20.93K
Market Cap:4.31M
PE:-1.09
High:2.86
Open:2.83
Low:2.68
Close:2.70
Loading ...

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

TIPRANKS
·
09 Apr

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

ACCESS Newswire
·
09 Apr

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

ACCESS Newswire
·
26 Mar

Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
20 Mar

Xenetic Biosciences Net Loss For The Year Ended December 31, 2024 Was ~$4M; Ended The Year With ~$6.2M Of Cash

Benzinga
·
19 Mar

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

ACCESS Newswire
·
19 Mar

Xenetic Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
18 Mar

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

ACCESS Newswire
·
13 Mar

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

ACCESS Newswire
·
27 Feb

Xenetic extends research collaboration with University of Virginia

TIPRANKS
·
16 Dec 2024

Xenetic enters clinical trial services agreement with PeriNess

TIPRANKS
·
05 Dec 2024

H.C. Wainwright Sticks to Their Hold Rating for Xenetic Biosciences (XBIO)

TIPRANKS
·
22 Nov 2024

Xenetic presents preclinical data on DNase I with CAR T cells in murine model

TIPRANKS
·
21 Nov 2024

Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
15 Nov 2024

Xenetic Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Xenetic Biosciences Q3 EPS $(0.28) Misses $(0.20) Estimate, Sales $614.24K Beat $230.00K Estimate

Benzinga
·
13 Nov 2024

Xenetic Biosciences Q3 Net Income USD -400 Thousand

THOMSON REUTERS
·
13 Nov 2024

Xenetic Biosciences: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Xenetic extends research collaboration with Scripps Research Institute

TIPRANKS
·
07 Nov 2024

Xenetic Biosciences - Extends Research, Development Collaboration With Scripps Research Institute to Advance Dnase Platform

THOMSON REUTERS
·
07 Nov 2024